Notably, some studies in animal models indicate that FXR antagonists, rather than agonists, may be more effective in resolving NASH.[53, 54, 55] In addition, FXR antagonists could be used in the treatment of obstructive cholestasis, supported by recent findings that FXR gene ablation protects against liver injury caused by bile duct ligation (BDL).[56]. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.